Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19‐9 predict risk of malignancy
Voss, Jesse S. , Jenkins, Sarah M. , Lingineni, Ravi K., Clayton, Amy C., Roberts, Lewis R. , Halling, Kevin C. , Talwalkar, Jayant A., Kipp, Benjamin R. , Barr Fritcher, Emily G, Fritcher, Emily G. Barr , Gores, Gregory J. , Roberts, Lewis R

Cancer Cytopathology | July 9, 2013 | Volume: 121 | Issue: 12 | Pages: 708-717

10.1002/cncy.21331 | PMID 23839915 Get It

BACKGROUNDPatients diagnosed with primary sclerosing cholangitis (PSC) and dominant strictures often undergo endoscopic retrograde cholangiopancreatography with brush cytology to exclude or confirm the development of malignancy. Equivocal (atypical or suspicious) routine cytologic results may confound patient management decisions, especially in the absence of a mass on imaging. The objective of the current study was to identify independent predictors of malignancy in patients with PSC with an equivocal cytology diagnosis.METHODSPatients with PSC underwent brush cytology for routine cytology and fluorescence in situ hybridization (FISH) during endoscopy as per standard care. FISH slides were classified as polysomy if at least 5 cells displayed a gain of ≥ 2 probes. A retrospective search identified 102 patients without a mass lesion noted on initial imaging studies, an equivocal routine cytology, and ≥ 2 years of follow‐up.RESULTSOf 102 patients, 30 (29%) with an equivocal cytology result developed cancer within 2 years. Serum carbohydrate antigen 19‐9 (CA 19‐9) levels ≥ 129 U/mL (hazard ratio [HR] 3.19; P = .001) and polysomy (HR 8.70; P < .001) were each found to be predictive of cancer. Of 10 patients who had elevated CA 19‐9 levels and polysomy, all went on to develop cancer (9 within 2 years). Although only 10 patients were included in this subset, the combination of elevated CA 19‐9 and polysomy was found to be predictive of cancer (HR 10.92; P < .001).CONCLUSIONSPolysomy by FISH identified those patients most likely to have or develop malignancy in the challenging clinical scenario of PSC with no mass at baseline and equivocal cytology. The combination of an elevated serum CA 19‐9 level with polysomy is highly suspicious for the presence of malignancy. Cancer (Cancer Cytopathol) 2013;121:708–717. © 2013 American Cancer Society.
Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation
Czuczman, Myron S., Zinzani, Pier Luigi , Reeder, Craig B. , Tuscano, Joseph M. , Lossos, Izidore S. , Pietronigro, Dennis, Vose, Julie M. , Habermann, Thomas M. , Li, Ju , Witzig, Thomas E. , Zinzani, Pier Luigi

British Journal of Haematology | July 9, 2013 | Volume: 162 | Issue: 5 | Pages: 639-647

10.1111/bjh.12449 | PMID 23834234 Get It

SummaryPatients with aggressive non‐Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL‐002 and NHL‐003) that studied single‐agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B‐cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression‐free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5‐month follow‐up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single‐agent lenalidomide.
Participation in Cardiac Rehabilitation and Survival After Coronary Artery Bypass Graft Surgery
Pack, Quinn R. , Lahr, Brian D. , Greason, Kevin L. , Squires, Ray W. , Thomas, Randal J. , Goel, Kashish , López-Jiménez, Francisco , Zhang, Zixin , Thomas, Randal

Circulation | July 9, 2013 | Volume: 128 | Issue: 6 | Pages: 590-597

10.1161/circulationaha.112.001365 | PMID 23836837 Get It

Background— Cardiac rehabilitation (CR) is recommended for all patients after coronary artery bypass surgery, yet little is known about the long-term mortality effects of CR in this population. Methods and Results— We performed a community-based analysis on residents of Olmsted County, Minnesota, who underwent coronary artery bypass surgery between 1996 and 2007. We assessed the association between subsequent outpatient CR attendance and long-term survival. Propensity analysis was performed. Cox proportional hazards regression was then used to assess the association between CR attendance and all-cause mortality adjusted for the propensity to attend CR. We identified 846 eligible patients (age 66±11 years, 76% men, and 96% non-Hispanic whites) who survived at least 6 months after surgery, of whom 582 (69%) attended CR. During a mean (±SD) follow-up of 9.0±3.7 years, the 10-year all-cause Kaplan-Meier mortality rate was 28% (193 deaths). Adjusted for the propensity to attend CR, participation in CR was associated with a 10-year relative risk reduction in all-cause mortality of 46% (hazard ratio, 0.54; 95% confidence interval, 0.40–0.74; P <0.001) and a 10-year absolute risk reduction of 12.7% (number needed to treat=8). There was no evidence of a differential effect of CR on mortality with respect to age (≥65 versus <65 years), sex, diabetes, or prior myocardial infarction. Conclusions— CR attendance is associated with a significant reduction in 10-year all-cause mortality after coronary artery bypass surgery. Our results strongly support national standards that recommend CR for this patient group.
Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of in vivo assessment of ventricular function in rats
Richardson, JD, Bertaso, AG, Psaltis, Peter J. , Koschade, B., Wong, DT, Nelson, Adam J. , Paton, Sharon , Williams, K., Azarisman, Shah M., Worthley, MI, Teo, KS, Gronthos, Stan , Zannettino, ACW, Worthley, SG, Frost, Lars , Carbone, Arnaldo , Zannettino, ACW, Worthley, Stephen G.

Laboratory Animals | July 8, 2013 | Volume: 47 | Issue: 4 | Pages: 291-300

10.1177/0023677213494373 | PMID 23836849 Get It

In vivo assessment of ventricular function in rodents has largely been restricted to transthoracic echocardiography (TTE). However 1.5 T cardiac magnetic resonance (CMR) and transoesophageal echocardiography (TOE) have emerged as possible alternatives. Yet, to date, no study has systematically assessed these three imaging modalities in determining ejection fraction (EF) in rats. Twenty rats underwent imaging four weeks after surgically-induced myocardial infarction. CMR was performed on a 1.5 T scanner, TTE was conducted using a 9.2 MHz transducer and TOE was performed with a 10 MHz intracardiac echo catheter. Correlation between the three techniques for EF determination and analysis reproducibility was assessed. Moderate-strong correlation was observed between the three modalities; the greatest between CMR and TOE (intraclass correlation coefficient (ICC) = 0.89), followed by TOE and TTE (ICC = 0.70) and CMR and TTE (ICC = 0.63). Intra- and inter-observer variations were excellent with CMR (ICC = 0.99 and 0.98 respectively), very good with TTE (0.90 and 0.89) and TOE (0.87 and 0.84). Each modality is a viable option for evaluating ventricular function in rats, however the high image quality and excellent reproducibility of CMR offers distinct advantages even at 1.5 T with conventional coils and software.
Human Calmodulin-Like Protein CALML3: A Novel Marker for Normal Oral Squamous Mucosa That Is Downregulated in Malignant Transformation
Brooks, Michael , Bennett, Richard D., Weaver, Amy L. , Sebo, Thomas J., Eckert, Steven E, Strehler, Emanuel E. , Carr, Alan B.

International Journal of Dentistry | July 8, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-8

10.1155/2013/592843 | PMID 23935623 Get It

Oral cancer is often diagnosed only at advanced stages due to a lack of reliable disease markers. The purpose of this study was to determine if the epithelial-specific human calmodulin-like protein (CALML3) could be used as marker for the various phases of oral tumor progression. Immunohistochemical analysis using an affinity-purified CALML3 antibody was performed on biopsy-confirmed oral tissue samples representing these phases. A total of 90 tissue specimens were derived from 52 patients. Each specimen was analyzed in the superficial and basal mucosal cell layers for overall staining and staining of cellular subcompartments. CALML3 was strongly expressed in benign oral mucosal cells with downregulation of expression as squamous cells progress to invasive carcinoma. Based on the Cochran-Armitage test for trend, expression in the nucleus and at the cytoplasmic membrane significantly decreased with increasing disease severity. Chi-square test showed that benign tissue specimens had significantly more expression compared to dysplasia/CIS and invasive specimens. Dysplasia/CIS tissue had significantly more expression than invasive tissue. We conclude that CALML3 is expressed in benign oral mucosal cells with a statistically significant trend in downregulation as tumorigenesis occurs. CALML3 may thus be a sensitive new marker for oral cancer screening.
Cramp‐fasciculation syndrome in patients with and without neural autoantibodies
Liewluck, Teerin , Klein, Christopher J. , Jones, Lyell K. , Liewluck, T , Klein, Christopher J , Jones, Lyell K

Muscle & Nerve | July 8, 2013 | Volume: 49 | Issue: 3 | Pages: 351-356

10.1002/mus.23935 | PMID 23836298 Get It

ABSTRACTIntroduction: We investigated the clinical, electrophysiological and neural autoantibody characteristics in cramp‐fasciculation syndrome (CFS) patients. Methods: We reviewed Mayo Clinic records from 2000 to 2011 to identify clinically defined CFS patients who underwent neural autoantibody testing. Stored sera of patients who tested positive for antibodies to voltage‐gated potassium channel complex (VGKC complex) were analyzed further for leucine‐rich glioma‐inactivated 1 (LGI1) or contactin‐associated protein‐2 immunoglobulin G (CASPR2‐IgG) antibodies. Results: Thirty‐seven patients were identified. Twelve were seropositive for neural autoantibodies. Clinical manifestations were similar in seropositive and seronegative patients, although central and autonomic neuronal hyperexcitability symptoms were more common in seropositive cases. No patients had a malignancy. Repetitive tibial nerve stimulation at 10 Hz revealed longer afterdischarges in seropositive patients. Two of 7 patients with VGKC‐complex autoimmunity demonstrated LGI1 or CASPR2‐IgG antibodies. Only 2 of 12 seropositive patients required immunotherapy. Conclusions: VGKC‐complex autoimmunity occurs in a minority of CFS patients. Antibody positivity was associated with extramuscular manifestations, typically without malignancy. Target antigens within the VGKC complex remain unknown in most patients. Muscle Nerve 49:351–356, 2014
Multifocal neuropathy as the presenting symptom of Purkinje cell cytoplasmic autoantibody-1
McKeon, Andrew , Klein, Christopher J. , Bradshaw, Michael , Haluska, Paul , Klein, Christopher J , McKeon, Andrew

Muscle & Nerve | July 8, 2013 | Volume: 48 | Issue: 5 | Pages: 827-831

10.1002/mus.23936 Get It

A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost
Channick, Richard N. , Frantz, Robert P. , Palevsky, Harold I. , Tumuluri, Ramagopal, Sulica, Roxana, Lauto, Paula, Benton, Wade W. , Boisblanc, Bennett de, Channick, Richard N. , Kawut, Steven M. , Frantz, Robert P

Pulmonary Circulation | July 8, 2013 | Volume: 3 | Issue: 2 | Pages: 381-388

10.4103/2045-8932.114768 | PMID 24015339 Get It

Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance, leading to right heart failure and death. Guidelines recommend customization of treatment, necessitating the development of effective strategies for transitioning patients among treatments. In this study, we characterized our experience with patient transitions from parenteral prostacyclin to inhaled iloprost. We retrospectively assessed records from 11 centers of 37 consecutive patients with PAH aged ≥ 18 years who were treated with intravenous (IV) or subcutaneous (SC) prostacyclin analogues and transitioned to inhaled iloprost. The transition period began on the first day of inhaled iloprost with the intent of discontinuing parenteral prostacyclin and ended on the first day on inhaled iloprost free of parenteral prostacyclin. Persistence was defined as the absence of (1) parenteral prostacyclin while remaining on inhaled iloprost during post‐transition Days 1–90 and (2) no reinitiation of parenteral prostacyclin during post‐transition Days 90–365. All patients were clinically stable before transitioning to inhaled iloprost. The mean age was 46.5 years, 70.3% were female, 51.4% had idiopathic PAH, and 43.0% were in New York Heart Association Functional Class III. Among patients with an overlapping transition, the mean transition period was 10.5 days. A transition dosing algorithm was used in 10 patients (27.0%). At one year, 78.4% of the patients remained persistent on inhaled iloprost and 81.1% were free of clinical worsening. In selected patients on background oral PAH therapy, transitioning from parenteral prostacyclin to inhaled iloprost appears safe and feasible and is associated with long‐term success. Further study is needed to define the optimal patient selection criteria and transition algorithm.
Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS
Macklin, Eric A. , Atassi, Nazem , Bowser, Robert , Cudkowicz, Merit , Fournier, Christina , Ladha, Shafeeq , Lacomis, David , Quinn, Colin , Boylan, Khrista , Berry, James D. , Ladha, Shafeeq , Cudkowicz, Merit E

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | July 8, 2013 | Volume: 14 | Issue: 7-8 | Pages: 632-634

10.3109/21678421.2013.808227 | PMID 23834161 Get It

Population‐based analysis of prostate‐specific antigen ( PSA ) screening in younger men (
Ranasinghe, Weranja , Kim, Simon P. , Lawrentschuk, Nathan , Sengupta, Shomik , Hounsome, Luke , Barber, Jim, Persad, Raj , Jones, Richard , Davis, Paul Andrew , Bolton, Damien Michael

BJU International | July 8, 2013 | Volume: 113 | Issue: 1 | Pages: 77-83

10.1111/bju.12354 | PMID 24053128 Get It

Objective To analyse the trends in opportunistic PSA screening in A ustralia, focusing on younger men (<55 years of age), to examine the effects of this screening on transrectal ultrasonography ( TRUS )‐guided biopsy rates and to determine the nature of prostate cancers ( PC as) being detected. Subjects and Methods All men who received an opportunistic screening PSA test and TRUS ‐guided biopsy between 2001 and 2008 in A ustralia were analysed using data from the A ustralian C ancer registry ( A ustralian I nstitute of H ealth and W elfare) and Medicare databases. The V ictorian cancer registry was used to obtain G leason scores. Age‐standardized and age‐specific rates were calculated, along with the incidence of PC a, and correlated with G leason scores. Results A total 5 174 031 PSA tests detected 128 167 PC as in the period 2001–2008. During this period, PSA testing increased by 146% (a mean of 4629 tests per 100 000 men annually), with 80 and 59% increases in the rates of TRUS ‐guided biopsy and incidence of PC a, respectively. The highest increases in PSA screening occurred in men <55 years old and up to 1101 men had to be screened to detect one incident case of PC a (0.01%). Screening resulted in two thirds of men aged <55 years receiving a negative TRUS biopsy. There was no correlation with G leason >7 tumours in patients aged <55 years. Conclusion Despite the ongoing controversy about the merits of PCa screening, there was an increase in PSA testing, especially in men <55 years old, leading to a modestly higher incidence of PC a in A ustralia. Overall, PSA screening was associated with high rates of negative TRUS ‐biopsy and the detection of low/intermediate grade PCa among younger patients.